Ionis Pharmaceuticals EVP Brian Birchler sells $176,580 worth of stock By Investing.com
Brian Birchler, executive vice president of corporate and development operations at Ionis Pharmaceuticals Inc. (NASDAQ:), recently sold 5,400 shares of the company’s stock. The shares were sold at an average price of $32.70 each, for a total transaction value of approximately $176,580. The transaction comes as Ionis is trading near a 52-week low of $31.40, with shares down about 38% over the past year. According to InvestingPro analysis, the company appears to be fairly valued at current levels.
In addition to the sale, Birchler acquired 14,283 shares of common stock on January 15, 2025, at no cost, as part of the vesting and release of shares of Restricted Stock Units. After these transactions, Birchler directly holds 55,051 shares of Ionis Pharmaceuticals.
The transactions were part of a structured plan to address withholding tax liabilities under the 2011 Capital Incentive Plan.
In other recent news, Ionis Pharmaceuticals is making significant strides in the pharmaceutical industry. The US Food and Drug Administration (FDA) recently approved Ionis’ drug TRYNGOLZA for the treatment of familial chylomicronemia syndrome (FCS). The approval represents a significant milestone for Ionis Pharmaceuticals as it moves into a new phase of commercial drug distribution. The company plans to transition patients from the Open-Label Extension (OLE) and Expanded Access Program (EAP) to the commercial drug during the first half of 2025. Analyst firms Piper Sandler and Needham maintained positive ratings on Ionis, with revenue forecasts for TRYNGOLZA projecting $37 million in revenue of US FCS for fiscal year 2025. Furthermore, the company announced its third quarter 2024 financial results, with an emphasis on non-GAAP financials, reflecting its operational management and long-term prospects. These recent developments highlight the progress and potential of Ionis Pharmaceuticals in the pharmaceutical industry.
This article was generated with the help of AI and reviewed by an editor. See our T&C for more information.